cro.directory
← Compare landing

ICON vs Premier Research

Auto-generated comparison by BioBM Editorial AI. This page highlights available profile evidence side by side and avoids drawing conclusions from missing fields.

Markdown mirror: /api/markdown/compare/kcrcro/premier-research

CategoryICONPremier Research
Listed sitecrocro
SummaryICON is a CRO with 8,000 biotech-dedicated professionals offering end-to-end clinical development, consulting, and therapeutic expertise across all development phases.Premier Research is a global full-service CRO delivering clinical research and development solutions across the complete drug development lifecycle. The organization provides comprehensive capabilities spanning study design, study startup, medical affairs, biostatistics and data management, central monitoring, clinical monitoring and site management, project and risk management, safety and pharmacovigilance, quality and compliance, and medical writing.
Services
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Clinical Trial Services
  • Clinical Imaging Core Lab
  • Central Laboratory Services
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Regulatory Affairs
  • Medical Writing
  • Cardiovascular & Metabolic Specialty Services
  • CNS Specialty Services
  • Oncology Specialty Services
  • Immunology & Inflammation Services
  • Virology Services
  • Biostatistics & Statistical Programming
  • Data Management & eClinical
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
  • Phase I Clinical Trials
  • Phase II Clinical Trials
  • Phase III Clinical Trials
  • Phase IV / Post-Marketing
  • Clinical Operations
  • Clinical Trial Services
  • Data Management & eClinical
  • Biostatistics & Statistical Programming
  • Medical Writing
  • Pharmacovigilance & Drug Safety
  • Central Laboratory Services
  • Regulatory Affairs
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • Japan PMDA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Translational Research
  • GLP Toxicology
  • Safety Pharmacology
  • In Vitro ADME / DMPK
  • In Vitro Pharmacology
  • Preclinical In Vitro Studies
  • In Vivo PK / PD Studies
  • In Vivo Efficacy Models
  • Preclinical In Vivo Studies
  • Device & Combination Product Services
Modalities
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • Small Molecule
  • Biologics (Monoclonal Antibodies)
  • Biologics (Other)
  • Cell Therapy
  • Gene Therapy
  • Vaccine
  • Peptide
Indications
  • Oncology
  • Neurology
  • Metabolic
  • Cardiovascular
  • Infectious Disease
  • Rare Disease
  • Women's Health
  • Oncology
  • Immunology
  • Neurology
  • Infectious Disease
  • Rare Disease
  • Dermatology
  • Women's Health
LocationsData not yet provided.
  • Headquarters, Morrisville, NC, United States
  • Southbank, Southbank, VIC, Australia
  • Sofia, Sofia, Bulgaria
  • Toronto, Mississauga, ON, Canada
  • Prague, Praha, Czech Republic
  • Paris, Paris, France
  • Darmstadt, Darmstadt, Germany
  • Budapest, Budapest, Hungary
  • Bengaluru, Bengaluru, India
  • Auckland, Auckland, New Zealand
  • Warsaw, Warszawa, Poland
  • Bucharest, Bucharest, Romania
  • Bratislava, Bratislava, Slovakia
  • Seoul, Seoul, South Korea
  • Madrid, Madrid, Spain
  • Taipei, Taipei, Taiwan
  • Kyiv, Kyiv, Ukraine
  • Wokingham, Wokingham, Berkshire, United Kingdom
CertificationsData not yet provided.Data not yet provided.
ReviewsReview summary appears after site-level review signal gate opens.Review summary appears after site-level review signal gate opens.